Diflunisal

Chemical formula: C₁₃H₈F₂O₃  Molecular mass: 250.198 g/mol  PubChem compound: 3059

Therapeutic indications

Diflunisal is indicated for:

Hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy

Population group: only adults (18 years old or older)

Diflunisal is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Diflunisal is contraindicated in the following cases:

Lactation

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe hepatic impairment

Hepatic failure stage IV

Pregnancy - third trimester

Pregnancy

Active gastro-intestinal bleeding

Gastrointestinal hemorrhage

Severe heart failure

Cardiac failure

Previous acute asthmatic attacks, urticaria, rhinitis or angioedema precipitated by NSAIDs

at least one of
Aspirin-induced asthma
NSAID-induced angio-oedema-urticaria
NSAID-induced angio-oedema-urticaria

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: ATTROGY Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈